Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care
This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only.
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021
Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2416 March 2022
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022
Management of venous thromboembolism in primary care
This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022